Kodiak Sciences Inc.
KODNasdaq
$42.64
↑ +3.4%Jul 17 close · end-of-day
Price
1Y↑ +800.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.6B
Enterprise Value
$2.5B
P/E
—
P/S
—
P/B
23.5
EV/EBITDA
—
PEG
—
FCF Yield
-5.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$230.7M
Free Cash Flow (TTM)
-$148.1M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-205.8%
ROIC
—
Debt / Equity
—
Net Cash
$169.5M
Return 1Y
+721.6%
Company profile
Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD) The company was formerly known as Oligasis, LLC.
- CEO
- Victor Perlroth
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- California
- Website
- kodiak.com
Management & directors
- Borgeson John A.Chief Financial Officer
- Perlroth VictorChairman and CEO
Roles derived from SEC Form 4 filings.
Earnings
KOD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.94↓ -13.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$136.0M | -$267.1M | -$341.4M | -$277.3M | -$186.8M | -$234.4M |
| Net income | -$133.1M | -$267.0M | -$333.8M | -$260.5M | -$176.2M | -$230.0M |
| Diluted EPS | -$2.91 | -$5.16 | -$6.39 | -$4.97 | -$3.35 | -$4.32 |
| Operating cash flow | -$83.4M | -$182.3M | -$206.5M | -$154.2M | -$117.3M | -$136.0M |
| Free cash flow | -$87.2M | -$199.3M | -$243.5M | -$195.5M | -$117.7M | -$136.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$48.0M | -$46.6M | -$46.2M | -$59.1M | -$55.5M | -$62.4M | -$57.5M | -$59.8M |
| Net income | -$45.1M | -$43.9M | -$44.1M | -$57.5M | -$54.3M | -$61.5M | -$56.7M | -$58.2M |
| Diluted EPS | -$0.86 | -$0.84 | -$0.83 | -$1.09 | -$1.03 | -$1.16 | -$1.04 | -$0.94 |
| Operating cash flow | -$26.5M | -$21.2M | -$30.1M | -$29.1M | -$34.7M | -$32.9M | -$39.4M | -$40.0M |
| Free cash flow | -$26.5M | -$21.3M | -$30.2M | -$29.3M | -$34.8M | -$32.9M | -$39.4M | -$41.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 10, 2026
May 28, 2026
May 17, 2026
- 64d agoBoxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phasefool.com
- 64d agoWhy One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rallyfool.com
- 64d agoVir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Sharesfool.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-04 | BORGESON JOHN A.· Chief Financial Officer | Sale | 25,896 | $34.01 | $880,722.96 | filing |
| 2026-06-04 | BORGESON JOHN A.· Chief Financial Officer | Sale | 4,104 | $34.67 | $142,285.68 | filing |
| 2026-06-04 | BORGESON JOHN A.· Chief Financial Officer | Option exercise | 30,000 | $1.04 | $31,200.00 | filing |
| 2026-04-15 | BORGESON JOHN A.· Chief Financial Officer | Option exercise | 28,614 | $1.04 | $29,758.56 | filing |
| 2026-04-02 | BORGESON JOHN A.· Chief Financial Officer | Sale | 12,477 | $40.29 | $502,698.33 | filing |
| 2026-04-02 | BORGESON JOHN A.· Chief Financial Officer | Sale | 12,692 | $39.14 | $496,764.88 | filing |
| 2026-04-02 | BORGESON JOHN A.· Chief Financial Officer | Sale | 4,231 | $40.88 | $172,963.28 | filing |
| 2026-04-02 | BORGESON JOHN A.· Chief Financial Officer | Option exercise | 30,000 | $1.04 | $31,200.00 | filing |
| 2026-04-02 | BORGESON JOHN A.· Chief Financial Officer | Sale | 600 | $41.77 | $25,062.00 | filing |
| 2026-03-25 | PERLROTH VICTOR· Chairman and CEO | Option exercise | 300,000 | $1.04 | $312,000.00 | filing |
| 2025-12-18 | BAKER BROS. ADVISORS LP | Buy | 2,391,268 | $23.00 | $55.0M | filing |
| 2025-12-18 | BAKER BROS. ADVISORS LP | Buy | 217,428 | $23.00 | $5.0M | filing |
| 2025-06-17 | BORGESON JOHN A.· See Remarks | Sale | 723 | $3.65 | $2,639.67 | filing |
| 2025-06-15 | BORGESON JOHN A.· See Remarks | Option exercise | 1,875 | — | — | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.